In this new episode of our Covid series, we are joined by Bruce Hellman and Jonathan Stone at uMotif. Bruce is the Co-Founder of the organisation, a leading patient centric eclinical platform. Jonathan is their Global Head of BD, having joined the organisation from Medidata as a multi-award winning sales professional. In this podcast, Bruce and Jonathan discuss the possible implications of Covid-19 on the biopharmaceutical and pharmatech markets.

Alan Greenberg is a Non- Executive Director with global expertise gained across a number of edtech’s, as well as advising VC’s and banks investing in the education sector and across the wider technology landscape. Alan was formally Director Apple Education EMEA and then Asia and interestingly, led the team who built Education Podcasting. In this podcast, Alan discusses his view on the possible implications of Covid-19 on the global education sector.

Dominic Farmer has been in the industry for 25 years having established Cisiv, a leading player in late phase and real world evidence solutions, in 1998. In this podcast, Dominic discusses his view on the possible implications of Covid-19 on the pharmaceutical technology space.

Matt Robb is Managing Partner at EY-Parthenon, where he leads the European education practice. During his career, Matt has worked in both public and private sectors within the education industry and has led work across every stage and sub-sector of education in the UK and across Europe including K-12, vocational and further education, universities and support services. In this podcast, Matt discuss the possible implications of Covid-19 on the investment space in education.

Julie Mercer has over 30 year’s experience in global management consultancy, particularly focused in education, and has supported education systems on an international basis. Having previously set up and then led the growth of Education at Deloitte, Julie is now Lead Partner at Cairneagle Associates for Higher Education and transformation. In this podcast, Julie discusses the possible implications of Covid-19 on strategic and management consultancy, as well as to Higher Education.

Steve Powell is a renowned, international  expert with a career spanning over 30 years within pharmaceutical technology. He has worked for organisations such as GSK and Phase Forward and now has a number of NED and Chair positions supporting technology businesses across eCOA, late phase, informatics and pharmacovigilance. In this podcast, Steve discusses the possible implications of Covid-19 on the pharmaceutical technology sector.

Today we continue our podcast series with a leading figure in the pharmaceutical technology market, Mike Nolte. Mike has a background of c.15 years in medtech, having also worked in major strategic consultancy environments.

Pat Hughes is currently the Chief Commercial Officer at Cluepoints and has been in the industry for over 20 years. In this podcast, Pat discusses his view on the possible implications of Covid-19 on RBM and the wider pharmatech market.

 

Julian Jeffrey is an internationally experienced school leader with a career spanning across 23 years at Wellington College. As the current Master at Wellington College International Tianjin, Julian discusses how he has managed the operation of online education in the K-12 setting since February, as well as the longer term implications of Covid on the bilingual and international schools market as they look to reopen in China.

Mark Maietta has a career spanning across 20 years including leadership roles in organisations such as Pfizer, CRF and Clariness. He is currently the President and Chief Commercial Officer at YPrime, a major player in eCOA, IRT, clinical data science and analytics. In this podcast, Mark discusses his view on the possible short, medium and long term implications of Covid on the pharmaceutical sector.

1 3 4
 
 

News & Blog Archive